A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Public ClinicalTrials.gov record NCT03947255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Study identification
- NCT ID
- NCT03947255
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Seagen Inc.
- Industry
- Enrollment
- 12 participants
Conditions and interventions
Interventions
- brentuximab vedotin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2019
- Primary completion
- Nov 5, 2022
- Completion
- Nov 5, 2022
- Last update posted
- Oct 12, 2023
2019 – 2022
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Cancer Medical Center | Anaheim | California | 92801 | — |
| SCL Health Good Samaritan Medical Center Cancer Centers of Colorado | Lafayette | Colorado | 80026 | — |
| Memorial Cancer Institute | Pembroke Pines | Florida | 33028 | — |
| Northwest Oncology and Hematology/AMITA | Elk Grove Village | Illinois | 60007 | — |
| Cardinal Bernardin Cancer Center / Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Tulane University Hospital and Clinic | New Orleans | Louisiana | 70112 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Karmanos Cancer Institute / Wayne State University | Detroit | Michigan | 48201 | — |
| Saint Louis University | St Louis | Missouri | 63103 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Summit Medical Group | Florham Park | New Jersey | 07932 | — |
| Medical University of South Carolina/Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Texas Oncology - Fort Worth | Dallas | Texas | 75246 | — |
| Texas Oncology - Fort Worth 12th Avenue | Fort Worth | Texas | 76104 | — |
| The Center for Cancer and Blood Disorders: Fortworth | Fort Worth | Texas | 76104 | — |
| MD Anderson Cancer Center / University of Texas | Houston | Texas | 77030-4095 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology - San Antonio Medical Center | San Antonio | Texas | 78240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03947255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 12, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03947255 live on ClinicalTrials.gov.